RSSDrug Development

Clinician- and Patient-reported Endpoints in CNS Orphan Drug Clinical Trials: ISCTM Position Paper on Best Practices for Endpoint Selection, Validation, Training, and Standardization

Clinician- and Patient-reported Endpoints in CNS Orphan Drug Clinical Trials: ISCTM Position Paper on Best Practices for Endpoint Selection, Validation, Training, and Standardization

| October 1, 2021

by Joan Busner, PhD; Gahan Pandina, PhD; Silvia Zaragoza domingo PhD; Anna-Karin Berger PhD; Maria T. Acosta, MD; Nahome Fisseha, PharmD; Joseph Horrigan, MD; Jelena Ivkovic, MD; William Jacobson, PhD; Dennis Revicki, PhD; and Victoria Villalta-Gil, PhD, MSc All authors are members of the ISCTM Working Group for Rare Disease/Orphan Drug Development; Drs. Busner and Pandina […]

Continue Reading

The Effect of Acutely Administered Propofol on Forced Swim Test Outcomes in Mice

The Effect of Acutely Administered Propofol on Forced Swim Test Outcomes in Mice

| September 1, 2019

by David G. Daniel, MD; Noah G. Daniel; Donald T. Daniel; Laura Copeland Flynn, MS; and Michael H. Allen, MD Dr. Daniel is with Bioniche Global Development, LLC in McLean, Virginia and the George Washington University in Washington DC. Mr. N. Daniel is with Dartmouth College in Hanover, New Hampshire. Mr. D. Daniel is with […]

Continue Reading

Correlation Between the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale and Nonmotor Scales in Patients with Parkinson’s Disease

Correlation Between the Movement Disorder Society’s Unified Parkinson’s Disease Rating Scale and Nonmotor Scales in Patients with Parkinson’s Disease

| September 1, 2019

by Erika D. Driver-Dunckley, MD; Nan Zhang, MS; Holly A. Shill, MD; Shyamal H. Mehta, MD, PhD; Christine M. Belden, PsyD; Edward Y. Zamrini, MD; Kathryn Davis; Thomas G. Beach, MD, PhD; and Charles H. Adler, MD, PhD Drs. Driver-Dunckley, Mehta, and Adler are with the Department of Neurology of the Parkinson’s Disease and Movement […]

Continue Reading

Is High Placebo Response Really a Problem in Depression Trials? A Critical Re-analysis of Depression Studies

Is High Placebo Response Really a Problem in Depression Trials? A Critical Re-analysis of Depression Studies

| July 1, 2019

by Mark E. Whitlock, PhD; Philip W. Woodward, MPhil; and Robert C. Alexander, MD Dr. Whitlock is BioStatistics Head of Internal Medicine, Early Clinical Development, for Pfizer in Cambridge, United Kingdom. Mr. Woodward is an independent statistics consultant in Newmarket, United Kingdom. Dr. Alexander is with Takeda Pharmaceuticals International Company in Cambridge, Massachusetts. Funding: No […]

Continue Reading

Letter to the Editor: The Click-through Rate as a Measure of Dementia Health Promotion on YouTube

Letter to the Editor: The Click-through Rate as a Measure of Dementia Health Promotion on YouTube

| July 1, 2019

Dear Editor: Social media platforms are increasingly used to disseminate health promotion and patient education.1–5 Impressions click-through rate (CTR) is the number of clicks on a health promotion and/or patient education ad, divided by the times the ad was shown on a social media platform. A recent study explored the practicality of Facebook advertising to […]

Continue Reading

Adult Neurogenesis in Humans: A Review of Basic Concepts, History, Current Research, and Clinical Implications

Adult Neurogenesis in Humans: A Review of Basic Concepts, History, Current Research, and Clinical Implications

| May 1, 2019

by Ashutosh Kumar, MD; Vikas Pareek, PhD; Muneeb A. Faiq, PhD; Sanjib K. Ghosh, MD; and Chiman Kumari, MD Drs. Kumar and Ghosh are with the Department of Anatomy at the All India Institute of Medical Sciences (AIIMS) in Patna, India. Dr. Pareek is with the Computational Neuroscience and Neuroimaging Division at National Brain Research […]

Continue Reading

Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis

Therapeutic Potential of Ponesimod Alone and in Combination with Dimethyl Fumarate in Experimental Models of Multiple Sclerosis

| March 1, 2019

by Laetitia Pouzol, MSc, PharmD; Luca Piali, PhD; Claude CA Bernard, PhD; Marianne M. Martinic, PhD; Beat Steiner, PhD; and Martine Clozel, MD Drs. Pouzol and Clozel were with Actelion Pharmaceuticals Ltd. in Allschwil, Switzerland, at the time of this research, and are presently with Idorsia Pharmaceuticals Ltd. in Allschwil, Switzerland. Dr. Piali was with […]

Continue Reading

Validation of an Equation Model to Predict Intracranial Pressure in Clinical Studies

Validation of an Equation Model to Predict Intracranial Pressure in Clinical Studies

| November 1, 2018

by Niro Kasahara, MD; Mateus L. Matuoka, MD; Katia S. Santos, MD; Natasha F.S. Cruz, MD; Alvaro R. Martins, MD; and Stanley Nigro, MD Drs. Kasahara, Matuoka, Santos, and Cruz are with the Department of Ophthalmology, Irmandade da Santa Casa de Misericordia de Sao Paulo in Sao Paulo, Brazil. Dr. Kasahara is also with Santa […]

Continue Reading